Kornimate/medical-research-clean huggingface dataset:
left chamber function in mitral regurgitation and predicting outcome after replacement and targeting for early surgery

Conditions: Mitral Regurgitation

Summary: the study aims to analyze the role of left ventricular and left atrial functional parameters by speckle tracking echocardiography in predicting outcome after mitral valve replacement and targeting for early intervention compared to guideline parameters.

without surgical treatment, the 10-year morbidity and mortality for patients with severe mitral regurgitation can be as high as 90%. in contrast, with successful surgical correction of mitral regurgitation before the appearance of symptoms, patients may have life expectancies similar to that of the general population. according to european recommendations, mitral valve replacement must be proposed to symptomatic patients and to patients with significant left ventricular remodeling as a consequence of the severity of mitral regurgitation. a significant decline in left ventricular function is defined, in these recommendations, echocardiographically as an left ventricular ejection fraction \ 45 mm. preoperative left ventricular systolic function and left ventricular end systolic diameter are important postoperative prognostic factors. the early detection of left ventricular systolic dysfunction remains a challenge. mitral regurgitation causes low left ventricular afterload, and the ejection fraction thus remains normal or supernormal until the disease reaches an advanced stage. some authors have suggested the additive value of deformation indices as more sensitive than the ejection fraction to detect subclinical left ventricular systolic dysfunction speckle tracking echocardiography has been well validated as a quantitative assessment tool for left ventricular function, and more recently this technique has been described for assessment of regional and global left atrial function

Eligibility criteria:
inclusion criteria: * patients with rheumatic severe mitral regurgitation who will have mitral valve replacement in assiut university heart hospital exclusion criteria: * degenerative mitral regurgitation, ischemic mitral regurgitation, severe rheumatic mitral regurgitation with atrial fibrillation or impaired left ventricular ejection fraction, associated mitral stenosis, or significant aortic regurgitation and ischemic heart disease.

Keywords: mitral regurgitation speckle echocardiography replacement
effect of tpvb on postoperative pain and cognitive function after vats in elderly patients

Conditions: Postoperative Cognitive Dysfunction; Acute Postoperative Pain; Chronic Postsurgical Pain

Summary: to investigate the effect of ultrasound-guided thoracic paravertebral nerve block on postoperative acute and chronic pain and cognitive function in elderly patients with thoracoscopic partial lung resection.

a total of 92 patients who were admitted to qinhuangdao first hospital for and divided into control group (group c ), thoracic paravertebral nerve block combined with general anesthesia group (group t). group c received general anesthesia, and group t received 0.375% ropivacaine 20 ml of thoracic paravertebral nerve block combined with general anesthesia after induction of anesthesia. sbp（systolic blood pressure）/dbp （diastolic pressure）and hr（heart rate） of the two groups were recorded before anesthesia induction (t1), at the time of intubation (t2), at the beginning of surgery (t5), immediately after surgery (t6), and five minutes after extubation (t7) . rsco2（regional cerebral oxygen saturation） was recorded in both groups at (t1), five minutes after induction(t3), five minutes after single lung ventilation on lateral recumbent(t4), (t6), (t7). the incidence of acute and chronic pain after surgery was compared between the two groups by nrs（numerical rating scale）after extubation , one day after surgery, and three months after surgery. the cognitive function of the two groups was assessed with the mini mental state scale (mmse) and the montreal cognitive assessment scale (moca-beijing) on the day before , one day after and three months after surgery, comparing the incidence of pnd (postoperative cognitive dysfunction) between the two groups.analyze whether paravertebral block can reduce the incidence of pod by improving brain oxygen saturation.

Eligibility criteria:
inclusion criteria: * bmi less than 30 kg/m2 * american society of anesthesiologists (asa) grades i-iii * the score of mini mental state examination≥24 * the score of montreal cognitive assessment-beijing scale≥26 exclusion criteria: * patients with heart, lung, brain and other vital organ disorders * the score of mini mental state examination≤23 * the score of montreal cognitive assessment-beijing scale≤25 * preoperative psychiatric disorders or long-term use of drugs affecting the psychiatric system * have severe visual, hearing, speech impairment or other inability to communicate with the visitor * have contraindications to thoracic parathymic block * refuse to sign informed consent

Keywords: thoracic paravertebral block cognitive function chronic postsurgical pain
familial breast cancer in china

Conditions: Breast Carcinoma; Genetic Variation

Summary: this study is a retrospective descriptive study to collect clinical data (mainly including medical records and follow-up information, etc.) of breast cancer patients with genetic variation who were first diagnosed and treated in a number of hospitals in china during the period from january 1, 2015 to december 31, 2024, and to establish a retrospective cohort of familial hereditary breast cancer. to analyze the clinical features, diagnosis and treatment and survival prognosis of patients with familial hereditary breast cancer. to explore the main factors affecting clinical diagnosis and treatment and survival prognosis of patients


Eligibility criteria:
inclusion criteria: * familial inherited breast cancer with genetic variants, including but not limited to mutations in the brca1, brca2, tp53, and palb2 genes * the patient had no major organ dysfunction * ecog score 0-1 exclusion criteria: * there are serious dysfunction of vital organs (heart, liver, kidney) * patients with other malignancies, except cured non-melanoma skin cancer, cervical carcinoma in situ and other tumors that have been cured for at least 5 years * in other acute infectious disease or chronic infectious disease activity period * a history of uncontrolled seizures, central nervous system disorders, or mental disorders
study evaluating the safety, tolerability, and efficacy of dexmecamylamine (tc-5214) for treatment of overactive bladder

Conditions: Overactive Bladder

Summary: overactive bladder (oab) is a syndrome characterized by symptoms of a sudden need to urinate with or without incontinence (leaking). the purpose of this study is to test whether dexmecamylamine is safe and effective compared to placebo for the treatment of symptoms of oab.

the study included a three- or five-week screening period, followed by a 12-week treatment period during which patients received either one of three doses of dexmecamylamine or placebo twice daily, randomized in a ratio of 2:1:1:1 (placebo, low dose, mid dose, high dose), with a two-week follow-up period. a total of 768 subjects with overactive bladder were randomized into the double-blind treatment period of the study.

Eligibility criteria:
inclusion criteria: * verified medical history of overactive bladder for at least 6 months * capable of walking unassisted to use the bathroom * able to measure voided urine volume and complete the diary without assistance * if the subject is currently being treated with an oab medication, the subject is willing to discontinue oab medications while participating in this study exclusion criteria: * diagnosis of a neurological disease affecting bladder function * stress incontinence, insensate incontinence, overflow incontinence or incontinence due to urinary fistula * history of incomplete bladder emptying, bladder outflow obstruction or post-void residual bladder volume \> 150 ml * males with benign prostatic hyperplasia or with a prostate-specific antigen (psa) of 4 ng/ml or more * other urinary tract pathology such as malignancy, ureteric reflux, bladder stone, uninvestigated hematuria, urethral stricture, or cystitis * prior treatment with intravesical or intraprostatic botulinum toxin in the last 2 years * myasthenia gravis * angle closure glaucoma * current implantation of interstim electrodes or vaginal surgical mesh * presence of a clinically significant medical condition at any time during the study * presence of clinically significant abnormalities in laboratory findings, physical exam findings or vital signs * participated in an investigational drug trial within 3 months of screening
a study to assess the efficacy of raltegravir (isentress®), administered in combination with other antiretroviral drugs as treatment for adults and older adults infected with the human immunodeficiency virus 1 (hiv-1)(mk-0518-145) (wirksamkeit von isentress® unter praxisbedingungen)

Conditions: HIV-1 Infection

Summary: this is an observational, non-comparative, multicenter, open-label study. participants will be treated with raltegravir according to standard clinical practice, and monitored over a total period of 96 weeks. in an extension to the study (amendment 1), a new cohort of aging participants (≥ 50 years) will be recruited and monitored over a total period of 48 weeks. participants who stop taking raltegravir before the end of the 96-week period or 48-week period, respectively, will be followed up for 3 months after discontinuing the drug. the primary objective is to determine the proportion of participants with a human immunodeficiency virus (hiv)-1 viral load \< 50 copies/ml after 48 weeks of treatment with raltegravir.


Eligibility criteria:
inclusion criteria the prospective participant must meet, at least, all of the criteria below to be eligible for study participation. the participant: * is a minimum age of 18 years (adults) or 50 years (aging participants); * is male or female; * has confirmed infection with hiv-1 (positive hiv test according to appropriate standard practice); * has commenced antiretroviral treatment with raltegravir according to the recommendations made in the summary of product characteristics at the time of enrollment on the study, or a maximum 6 months prior to enrollment on the study; * has any cluster of differentiation (cd4) cell (specialized white blood cell) count upon enrollment on the study. exclusion criteria if the prospective participant meets any of the criteria below (among others determined by the study staff) they will not be eligible for study participation. the participant: * for which raltegravir, or its ingredients, are contraindicated; * has intolerance to raltegravir, or its ingredients; * if female, is pregnant, breastfeeding, or is planning a pregnancy or egg donation during the study.

Keywords: hiv antiretroviral human immunodeficiency virus raltegravir adults with hiv-1 infection
study of cabiralizumab in patients with pigmented villonodular synovitis / diffuse type tenosynovial giant cell tumor

Conditions: Pigmented Villonodular Synovitis; Tenosynovial Giant Cell Tumor

Summary: this is a phase 1/2 single arm, open-label, safety, tolerability, and pk study of cabiralizumab in pvns/dt-tgct patients.

a phase 1/2 study was an open-label, dose escalation and dose expansion study designed to evaluate the pharmacokinetics, pharmacodynamics, safety and preliminary efficacy of cabiralizumab, a csf1-r monoclonal antibody, inpatients with unresectable diffuse tenosynovial giant cell tumors (tgct).

Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of inoperable pvns/ dt-tgct or potentially resectable tumor that would result in unacceptable functional loss or morbidity as determined by a qualified surgeon or multi-disciplinary tumor board (must be documented in the crf during screening) * measurable pvns/dt-tgct by recist 1.1 on mri * ecog performance status \<1 exclusion criteria: * prior therapy with an anti-csf1r antibody * prior therapy with plx3397 unless discontinued for intolerance (i.e., non-progression on prior kinase inhibitor) * liver function tests (including alt, ast, and total bilirubin), outside of the range of local laboratory normal at screening * inadequate organ or bone marrow function * history of congestive heart failure or myocardial infarction \<1 year prior to first study dose administration * significant abnormalities on ecg at screening * contraindications to mri and use of intravenous gadolinium-based contrast agents * creatine kinase ≥ 1.5x the upper limit of normal * positive test for latent tb at screening (quantiferon test) * active known or suspected autoimmune disease

Keywords: diffuse type tenosynovial giant cell tumor (dt-tgct)
health technology to improve exercise in axspa

Conditions: Axial Spondyloarthritis

Summary: despite the known benefits of physical activity, the majority of canadians fail to meet recommended guidelines. patients with axial spondyloarthritis (axspa) also fail to meet recommended guidelines. exercise, a critical component of physical activity, is considered the cornerstone of axspa management. simple health technologies such as mobile phone messaging and email can be useful tools to increase engagement in regular physical activity among the general public and patients with chronic disease. as such, the aim of this research project is to develop and test a patient-centered strategy that provides education on the importance of physical activity and utilizes existing health technologies (such as smart phone applications) to encourage regular participation in physical activity. the results of this study are expected to demonstrate that patients with axspa will increase their daily engagement in physical activity, and therefore improve symptoms, function and overall quality of life.


Eligibility criteria:
inclusion criteria: * adults (aged 18 and older) with a diagnosis of axspa based on asas criteria * have access to email and a smart phone device (android or ios operating systems) * enrolled in the sparcc research program * passes pre-participation health screen exclusion criteria: * non-english speaking * not enrolled in the sparcc research program * comorbidities or physical impairments that may preclude physical activity (e.g., symptomatic cardiovascular disease; wheelchair bound etc.)
the cire study (citrate recirculation study)

Conditions: Acute Kidney Injury

Summary: the aim of this study is to determine the effects of av port reversal (avpr) on recirculation, clearance, post-filter ionized calcium and subsequently citrate dosing.

rationale: av port reversal (avpr) has been demonstrated to increase recirculation in venous catheters used in icu for cvvh. the effects of this frequently used manoeuvre have not been described in the setting of cvvh using regional citrate anticoagulation. objective: the aim of this study is to determine the effects of avpr on recirculation, clearance, post-filter ionized calcium and subsequently citrate dosing. study design and methods: open trial studying the effect of avpr in patients undergoing citrate cvvh. after measurement in standard catheter configuration, avpr is performed after which effects on catheter recirculation, clearance, citrate dosing and post-filter ionized calcium (ica) are monitored. sample sites: arterial line, arterial (pre-filter) port, postfilter port (after postdilution and calcium compensation), effluent sample. all flow rates to be noted. study population: twelve patients admitted to intensive care, requiring continuous renal replacement therapy (crrt) for aki. patients are preferably anuric and have achieved good metabolic control under cvvh before inclusion in the study.

Eligibility criteria:
inclusion criteria: * critically ill patients requiring crrt for aki (rifle criteria) * written informed consent from the patient or legal representative * no av port reversal had taken place before inclusion in the study * diuresis is minimal or the patient is anuric so that effects of changes in clearance as a consequence of diuresis are minimalized and do not influence study outcomes. * the patient has undergone cvvh for a number of days, ensuring good metabolic control, so that possible short term loss of clearance as a consequence of av port reversal has no detrimental effects. exclusion criteria: * pre-existing chronic renal insufficiency requiring dialysis * chronic immunosuppression * liver cirrhosis child-pugh c * severe or shock-related hepatitis * pregnancy
visual outcomes after implantation of a new multifocal intraocular lens

Conditions: Cataract

Summary: this prospective nonrandomized study comprised patients with cataract, corneal astigmatism, and motivation for spectacle independence. in all cases, a rayner m-flex® t toric intraocular lens will be implanted in the capsular bag. three months postoperatively, distance, intermediate, and near visual acuities; spherical equivalent; residual refractive astigmatism; defocus curve; and contrast sensitivity will be evaluated. a patient-satisfaction and visual phenomena questionnaire will also be administered.

postoperative evaluation was performed at 3 months. the uncorrected and corrected distance visual acuity were assessed using the 100% contrast early treatment diabetic retinopathy study chart, uncorrected intermediate visual acuity at 70 cm, and uncorrected near visual acuity at 40 cm; a binocular defocus curve was constructed using the etdrs chart at 4 m and adding to the patient's manifest refraction +2.50 to -5.00 d sphere in 0.50 increments. the cylinder axis of the intraocular lens (iol) was measured at the slitlamp using the beam protractor after full mydriasis. the mean of the absolute values of degrees the intraocular lens was off axis was determined. contrast sensitivity was measured using the csv-1000 hgt instrument (vectorvision, inc.), which presents a translucent chart divided into 4 cycles with spatial frequencies of 3, 6, 12 and 18 cycles per degree. the background illumination of the translucent chart does not depend on room lighting. all measurements were obtained under mesopic (5 cd/m2) and photopic (85 cd/m2) conditions. the examinations were performed unilaterally at a distance of 2.5 m with best-corrected visual acuity (bcva) and an undilated pupil. all measurements were performed under the same conditions. patient satisfaction and quality of life were assessed by a simple questionnaire. patients were interviewed 3 months postoperative. patients were asked about visual disturbances, visual lifestyle activities, spectacle use, and satisfaction with the procedure.

Eligibility criteria:
inclusion criteria: * cataract * any race * either gender * diagnosis of cataracts both eyes * pre-existing physical conditions that could skew visual results, such as diabetes, retinal detachment, macular degeneration, or cancer * subjects must have \> 1.00 diopter of astigmatism exclusion criteria: * central endothelial cell count less than 2000 cells/mm2 glaucoma or intraocular pressure greater than 21 mmhg amblyopia * retinal abnormalities * diabetes mellitus steroid or immunosuppressive treatment * connective tissue diseases

Keywords: cataract vision intraocular lens multifocal toric
immunogenicity and safety of a third dose and immune persistence of bbibp-corv vaccine in elderly people with chronic bronchitis and copd

Conditions: COVID-19; Chronic Bronchitis; COPD

Summary: evaluation of immunogenicity, safety and persistence of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease received the third dose of inactivated covid-19 vaccine .

the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease recruited to receive a third dose of inactivated covid-19 vaccine. blood samples will be collected 3 times: before the third dose of vaccinatioin，28 days and 6 months after the third dose of vaccination. any local or systemic adverse events that occurred within 21 days after vaccination will be recorded.

Eligibility criteria:
inclusion criteria: * subjects aged 60 and above with full capacity for civil conduct; * chronic bronchitis (or chronic obstructive pulmonary disease) diagnosed by a medical institution at level i or above; * body temperature \< 37.3 ° c confirmed by clinical examination before enrollment ; * able and willing to complete the entire study plan during the study follow-up period; * have the ability to understand the study procedures, voluntarily sign informed consent, and comply with the requirements of the clinical study protocol; * subjects participating in the past clinical trial have completed two doses of covid-19 vaccine and blood collection before and after immunization; exclusion criteria: * subjects were previously confirmed cases of covid-19 or asymptomatic infected persons; * being allergic to any component of vaccines (including excipients) ; * injection of non-specific immunoglobulin within 1 month before enrollment; * injection of live attenuated vaccines within 1 month and injection of other vaccines within 14 days before enrollment; * subjects who have experienced severe allergic reactions to vaccines (e.g. acute anaphylaxis, urticaria, angioneurotic edema, dyspnea, etc.); * having uncontrolled epilepsy and other progressive neurological disorders and a history of guillain-barre syndrome; * having severe liver and kidney diseases, malignant tumors, acute diseases or acute episodes of chronic diseases; * have been diagnosed with congenital or acquired immunodeficiency, hiv infection, lymphoma, leukaemia or other autoimmune diseases; * have been diagnosed with thrombocytopenia or other clotting disorders that may contraindicate subcutaneous injection; * during an acute episode of chronic bronchitis/chronic obstructive pulmonary disease; * subjects who had vaccine-related adverse reactions after the second dose; * having high fever (axillary temperature ≥39.0℃) for three days after the second dose of inoculation, or severe allergic reaction; * having any adverse nervous system reaction after the second dose; * during the acute onset of a chronic disease, or the recovery of acute complications less than two weeks; * other reasons for exclusion considered by the investigator.
emotion regulation and cancer caregiving

Conditions: Breast Cancer; Cancer; Healthy; Emotions

Summary: the purpose of the study is to determine how the behaviors of cancer caregivers can impact patients.


Eligibility criteria:
inclusion criteria: all participants must: * be 21 years or older * have access to a computer with internet access patients must: * be women * have a diagnosis of breast cancer (non-recurrent) caregivers must be: -the patient's caregiver (providing support to the patient) exclusion criteria: participants must not be: -younger than 21 years patients must not: * be men * have a diagnosis other than breast cancer (non-recurrent)